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The aim of this prospective study was to assess the eYcacy, clinical bene®t and safety of CPT-11
(irinotecan) in patients with stringently-de®ned 5-¯uorouracil-resistant metastatic colorectal cancer
(CRC). 107 patients with documented progression of metastatic CRC during 5-FU were treated with
CPT-11 350 mg/m2 once every 3 weeks in a multicentre phase II study. Tumour response and toxicity
were assessed using WHO criteria. Changes in performance status (PS), weight and pain were also
measured. The WHO response rate was 13/95 (13.7%, 95% CI 7.5% to 22.3%) eligible patients with a
median duration of response of 8.5 months (37 weeks, range: 18±53 +). There was also a high rate of
disease stabilisation (44.2%) with a median duration of 4.8 months. The probability of being free of
progression at 4 months was 50%. Median survival from ®rst administration of CPT-11 was 10.4
months or 45 weeks (range: 3±66 + weeks). There was weight stabilisation or gain in 81% (73/90) of
patients, a favourable outcome in PS in 91% (82/90) (improvement of WHO PS 2 or stabilisation of PS
0-1), and pain relief in 54% (26/48). There were no toxic deaths. Neutropenia was short-lasting and
non-cumulative. Diarrhoea grade  3 occurred in 7% of cycles and 28/107 (26%) of patients. CPT-11
350 mg/m2 once every 3 weeks has an encouraging degree of activity in progressive metastatic CRC
truly resistant to 5-FU with a relatively high rate of tumour growth control translated into clinical
bene®t. The toxicity pro®le of CPT-11 is becoming better understood and has been considerably
improved. # 1999 Elsevier Science Ltd. All rights reserved.
Key words: chemotherapy, colon cancer, CPT-11, 5-FU resistant, irinotecan
Eur J Cancer, Vol. 35, No. 1, pp. 54±59, 1999
INTRODUCTION
Metastatic colorectal cancer (CRC) has often been
treated with systemic chemotherapy to palliate symptoms
rather than to improve survival [1]. However, two studies
have shown that patients who receive palliative chemo-
therapy at the time of diagnosis of metastatic CRC do better
than those who receive it only at the onset of symptoms [2],
or than those who do not receive chemotherapy [3], obtain-
ing signi®cant improvement in both survival and quality of
life.
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Although numerous cytotoxic agents have been tested in
metastatic CRC, regimens based on 5-¯uorouracil (5-FU)
have proved to be the most eVective, and a combination of 5-
FU and leucovorin (LV) is considered to be the standard
®rst-line chemotherapy [4]. There is, however, no standard
treatment for patients in whom 5-FU-based chemotherapy
has failed; no other cytotoxic agent has proved to be eVective.
A review by National Cancer Institute investigators found an
overall response rate for all new agents in this setting of 2.4%
[5]. Therefore, most attempts at second-line chemotherapy
comprise further 5-FU-modulated treatments. Overall,
approximately 10% of patients at most will respond to sec-
ond-line 5-FU-based chemotherapy, whatever the schedule
of 5-FU and/or the modulator agents might be [6, 7].
The water-soluble camptothecine derivative irinotecan [8]
(CPT-11), a DNA topoisomerase I inhibitor has a unique
mechanism of action. In previous phase II studies, CPT-11
has demonstrated activity in the treatment of both che-
motherapy-naõÈve and previously treated patients with CRC,
showing response rates of 15% to 32% [9±11]. In one large
French multicentre study, the response rate of metastatic
CRC to CPT-11 350 mg/m2 once every three weeks was 18%
in 178 eligible patients (48 previously untreated and 130
previously treated with 5-FU) [12]. Ten responses were
observed in 62 eligible patients (16.1%) whose disease had
progressed whilst receiving prior 5-FU-based chemotherapy,
this subgroup meeting the most stringent criteria for 5-FU-
resistant disease. In an American study, 48 patients with
advanced CRC who were previously treated with a 5-FU-
based regimen were treated with CPT-11 125 to 150 mg/m2
weekly for 4 weeks every 6 weeks. A response rate of 23% was
reported in 43 evaluable patients [11]. 37 of the patients
(77%) had progressed during prior 5-FU-based chemother-
apy; the response rate in this subgroup was not reported.
The present multicentre study was the ®rst study conducted
to assess prospectively the eYcacy, clinical bene®t and safety
of CPT-11 (Campto1; RhoÃne-Poulenc Rorer, Paris, France)
in patients with stringently-de®ned 5-FU-resistant disease
since, in the previous studies, 5-FU resistance was not shown
in all patients. In the light of previous experience, the present
protocol also placed particular importance on vigilance and
prompt aggressive treatment for delayed-onset diarrhoea.
PATIENTS AND METHODS
Twenty-®ve centres participated in this open-label, phase
II multicentre study. Ethics committee approval was obtained
and all patients gave written informed consent to participate.
Only patients with metastatic CRC who had developed
documented tumour progression during 5-FU administration
were admitted to the study.
Other inclusion criteria were: histologically proven cancer
of the colon or rectum; one prior chemotherapy regimen (two
if one was adjuvant); a washout period of at least 4 weeks
since the last treatment (6 weeks for mitomycin C, nitro-
sourea or extensive radiotherapy). Progression on 5-FU-
based therapy was de®ned as follows: two successive imaging
investigations within 6 months showing more than 25%
growth in target lesions or appearance of new lesions. An
adequate dosage and regimen of the prior 5-FU-based regi-
men was required (5-FU more than 500 mg/m2/week bolus or
600 mg/m2/week infusional). Other criteria were: measurable
disease outside a previously irradiated ®eld; age 18 to 70
years; WHO performance status (PS) of  2; life expectancy
of at least 12 weeks; normal haematological pro®le and ade-
quate renal and hepatic function.
Ineligibility criteria were: bulky disease (> 25% of lung or
> 50% of liver involved, or palpable abdominal mass); pre-
vious treatment with CPT-11 or any topoisomerase I inhi-
bitor; past in¯ammatory enteropathy or extensive bowel
resection; known brain metastases; history of other cancer;
severe uncontrolled infection; major organ failure; bowel
obstruction; childbearing potential.
Patients were treated with CPT-11 350 mg/m2 (maximum
700 mg) by intravenous (i.v.) infusion for 90 minutes once
every 3 weeks, with provision for dose reduction (to 300 mg/
m2 and further to 250 mg/m2) or delay if severe toxicity
(diarrhoea grade  3; neutropenia grade  3) occurred.
Treatment was to be continued for up to 9 cycles in the event
of either disease stabilisation or complete or partial response
but was to be terminated in the event of disease progression,
major toxicity or patient refusal. EYcacy was evaluated after
every 3 cycles. All progressions on 5-FU and all response
assessments were reviewed by an independent external
response review committee. Responses were determined
according to WHO criteria. Changes in performance status,
weight and pain were also measured. Safety was monitored at
each cycle (except haematology: weekly) and graded accord-
ing to WHO criteria where applicable. Diarrhoea was asses-
sed by means of a special questionnaire in addition to WHO
grading.
Preventive anti-emetic treatment was given routinely. If
cholinergic syndrome occurred it was to be treated with
atropine 0.25 mg subcutaneously (s.c.), and this could be
used prophylactically for subsequent cycles.
Both patients and physicians were alerted to the impor-
tance of recognising and reacting immediately to the onset of
delayed diarrhoea. If delayed diarrhoea occurred, it was to be
treated promptly with high-dose loperamide (2 mg every 2 h
for at least 12 h after the last loose stool). If it persisted for
more than 24 h despite loperamide treatment, an oral broad-
spectrum quinolone antibiotic was to be prescribed for 7
days. If the diarrhoea persisted for > 48 h loperamide was
stopped and the patient had to be hospitalised for parenteral
rehydration.
The European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ-
C30) was to be ®lled in by patients at baseline and before
each cycle. The patients graded pain as absent, mild, moder-
ate and severe.
The sample size was determined on the basis of a single-
stage Fleming design [13]. Using the assumption that CPT-
11 would not be of further interest in 5-FU-resistant CRC if
the response rate was less than 6%, but that a response rate of
16% would be of de®nite interest in this population, a mini-
mum sample size of 79 evaluable patients was needed. The
data are presented using descriptive statistics and Kaplan±
Meier estimations were employed for the analysis of censored
data.
RESULTS
Patient characteristics
107 patients received treatment in this study. Baseline
characteristics of the treated population are shown in Table 1.
The median time between last chemotherapy and entry to the
present study was 1.6 months (range: 0.3±13.7) and the
median time since documentation of progression on 5-FU
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was 1.5 months (0.2 to 13.8). The median delay between the
two computer tomography (CT) scans proving tumour pro-
gression on 5-FU was 3.2 months (maximum 6 months). 14
patients (13%) relapsed whilst receiving adjuvant therapy. 60
patients (56%) were symptomatic at study entry, as re¯ected
by a PS of 1 or 2. 12 patients were ineligible: 5 had no avail-
able baseline tumour assessment or were considered not to
have measurable disease by the external response review
committee; in 4 patients, disease progression was not con-
®rmed by the external response review committee; 2 had
bowel obstruction at baseline; 1 had more than one prior
palliative chemotherapy regimen; 1 had liver involvement of
more than 50%; 1 had a PS greater than 2. 2 of the 12
patients each had two reasons for ineligibility. Therefore, 95
(89%) patients are eligible.
Baseline lactic dehydrogenase (LDH) and white blood
cells were increased in 52 and 40% of patients, respectively.
Drug exposure
A total of 588 cycles of CPT-11 were administered; 483
(82%) at the planned dose of 350 mg/m2. The median num-
ber of cycles given was 6 (range: 1±12). 36 patients (34%)
received more than 6 cycles. Infusions were delayed by 7 days
or more in 11 cycles (2%) and the dose was reduced once or
more in 27 patients (25%) and in 100 cycles (17%). The
median relative dose intensity (de®ned as the actual dose
administered divided by the planned dose) was 0.97 (range:
0.62±1.08).
Among the 107 treated patients, the most frequent reason
for discontinuation of treatment was disease progression (76
patients including 1 patient who died during the study due to
this cause). 4 patients withdrew due to toxicity (described
below). Another 5 patients refused further treatment, and 19
discontinued because they had completed the nine cycles
called for in the study protocol. One patient was lost to follow
up. Median follow up was 57 weeks (range: 35±72).
EYcacy of CPT-11
The principal eYcacy results, based on the assessment of
the independent external response review committee, are
summarised in Table 2. 5 of the 95 eligible patients were not
evaluable: 2 because of inappropriate or missing evaluations;
1 each because of withdrawn consent, loss to follow-up, and
withdrawal due to toxicity before ®rst assessment.
The overall objective response rate in the 95 eligible
patients was 13.7% (95% CI 7.5% to 22.3%). Median dura-
tion of response was 8.5 months or 37 weeks (range: 18±53 +
weeks). Six of the 13 partial responses (PR) occurred at cycle
3. Of the remaining 7, 1 occurred at cycle 4 and 6 at cycle 6.
In addition to the 13 patients with a partial response, a fur-
ther 42 (44.2%) had stabilisation of their disease, which had
been progressive at baseline (Table 2). Included in the stable
disease category are 5 patients with `minor' responses,
de®ned as a regression of between 25 and 49% of the overall
tumour mass. In two cases, the observed tumour shrinkage
exceeded 40% at cycle 6. Median duration of stable disease
as best response was 4.8 months or 21 weeks (range: 15±
64 +). Responses on CPT-11 were seen in 18% (3/17)
patients having a previous response to 5-FU, as well as in
21% (7/33) patients with progressive disease as best evalua-
tion on 5-FU. PRs occurred in 5 of the 40 patients with liver
as only site of disease, 2 of the 7 patients with lung metastases
as the only site of disease, 2 of the 13 patients with liver and
lung as the only site of disease and 4 of the 35 patients with
multiple sites including the liver.
The median time to progression was 17 weeks (range: 1±
64 +). The probability of being free from progressive disease
was, therefore, 50% at 4 months (6 cycles); 27% at 6 months.
Median survival from ®rst administration of CPT-11 was
10.4 months or 45 weeks (range: 3±66 + weeks).
Evolution of body weight was considered in terms of the
number of patients with  3 cycles of therapy who experi-
enced weight loss  5%, stabilisation or gain  5%. Out of 90
evaluable patients, 73 (81%) had a stabilisation or gain in
weight. For WHO PS, a successful outcome was de®ned as
improvement from a baseline PS 2 for at least two con-
secutive cycles (64% had an improvement of PS 2 to 0±1
after 3 cycles and 77% after 6 cycles), or stabilization of
baseline PS 0-1 (69% of patients with PS 0 at baseline had
PS 0 after 3 cycles and 68% after 6 cycles; of patients with PS
1 at baseline, 62 and 72% remained at PS 1 after 3 and 6
cycles, respectively, and 11 and 24% improved to PS 0 after 3
and 6 cycles, respectively). On this criterion, 82 of the 90
evaluable patients (91%) had a successful outcome in terms
of evolution of WHO PS.
Of 48 patients who had pain at entry to the study, 26
(54%) had complete relief from pain. Of 59 patients who had
no pain at entry to the study, 50 (85%) remained free of pain.
These clinical bene®ts were particularly evident among the
patients who were free from disease progression at the end of
Table 1. Characteristics of patients at baseline
Treated patients
(n = 107)
Sex (M/F) 63/44
Median age (range) in years 58 (28±72)
Median WHO performance status (range) 1 (0±2)
Primary tumour
Colon 73 (68%)
Rectum 28 (26%)
Rectosigmoid 6 (6%)
Intent of prior 5-FU regimen
Adjuvant only 14 (13%)
Palliative only 76 (71%)
Adjuvant + palliative 17 (16%)
Best response to last palliative 5-FU regimen
(n = 85 pts with evaluable response))
Complete or partial response 17 (20%)
Stable disease 35 (41%)
Progressive disease 33 (39%)
Eligible patients 95 (89%)
Table 2. Response rate to CPT-11 in 95 eligible patients
(documented progressive disease on 5-FU) as determined by the
independent response review committee
Response Number of patients (%)
Complete response 0 ±
Partial response 13 (13.7)
Stable disease 42 (44.2)
Progressive disease 35 (36.8)
Not evaluable 5 (5.3)
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cycle 6. Seventy-three per cent of these patients were free of
pain, with PS 0 or 1 and without weight loss.
Safety and tolerability of CPT-11
One patient died due to progressive disease during the
study; there were no deaths attributed to toxicity of CPT-11.
4 patients discontinued treatment with CPT-11 due to
adverse events (1 due to haematological toxicity at cycle 1; 2
due to diarrhoea at cycles 1 and 7, respectively; 1 due to
deterioration in performance status at cycle 1). 27 patients
(25%) were hospitalised (15 due to diarrhoea) due to adverse
events possibly or probably related to CPT-11; there were 37
episodes of hospitalisation (6% of cycles) comprising: 18 for
diarrhoea with or without vomiting, 4 for diarrhoea asso-
ciated with febrile neutropenia/infection, 7 for febrile neu-
tropenia/infection, 6 for vomiting, 1 for drug-related fever
and chills, and 1 for anaemia requiring blood transfusion.
Thus diarrhoea was a causal event in 22/37 episodes of hos-
pitalisation (59%).
The principal haematological toxicity was neutropenia.
16% (17/107) of the patients had a grade 3 neutropenia and
25% (27/107) a grade 4. 10% of the cycles resulted in grade 3
and 7% in grade 4 neutropenia. The median nadir in neu-
trophil count was 1.9109 (range 0 to 9). The median num-
ber of days to nadir was 8 (range: 0±30). Of 93 cycles
resulting in grade 3 or 4 neutropenia, only one lasted longer
than 7 days. Neutropenia did not appear to be cumulative.
Fever and/or infection concomitant with grade 3 or 4 neu-
tropenia occurred in 9 patients (8%) and 9 cycles (2%).
Antibiotics were given in all cases.
Anaemia occurred in 61 of 106 evaluable patients (58%);
grade 3 or 4 in 12 patients (11%). Mild to moderate throm-
bocytopenia occurred in 6% (6/107) of patients and 2% of
cycles.
Non-haematological adverse events possibly or probably
related to treatment with CPT-11 that occurred in  3% of
patients are summarised in Table 3. Although the most fre-
quent were alopecia, asthenia, nausea/vomiting, diarrhoea
and cholinergic syndrome, the most frequently serious in
clinical terms was delayed-onset diarrhoea.
WHO Grade 3 or 4 delayed-onset diarrhoea occurred in
26% (28/107) of patients and 7% of cycles. However, the
median duration of any grade of diarrhoea was 3 days and of
grade 3 or 4 diarrhoea 5 days. The characteristics of delayed-
onset diarrhoea are detailed in Table 4. The incidence may
be overestimated, as the protocol stipulated that antidiar-
rhoeal treatment with loperamide should be started as soon as
the ®rst liquid stool was observed. 18 cycles (5% of the 350
with diarrhoea) resulted in only one liquid stool. Of the 94
patients with at least one episode of diarrhoea, 79 (84%) had
Table 3. Non-haematological adverse events possibly or probably related to treatment with CPT-11 and aVecting more
than 3% of patients
Type of adverse event Number (%) of patients with event (n = 107) Number (%) of cycles with event (n = 588)
All Grade 3 Grade 4 All Grade 3 Grade 4
Alopecia 97 (91) 63 (59) ± ± ± ±
Nausea/vomiting 94 (88) 17 (16) 3 (3) 325 (55) 54 (9) 3 (1)
Diarrhoea 94 (88) 25 (23) 3 (3) 350 (60) 38 (7) 3 (< 1)
Cholinergic syndrome* 88 (82) 10 (9) ± 275 (47) 13 (2) ±
Asthenia* 71 (66) 9 (8) ± 232 (40) 14 (2) ±
Mucositis (oral) 25 (23) 2 (2) ± 36 (6) 2 (< 1) ±
Anorexia* 25 (23) 3 (3) ± 60 (10) 5 (1) ±
Neurologic function 12 (11) ± ± 35 (6) ± ±
Constipation 8 (7) ± ± 16 (3) ± ±
Fever in absence of infection
without grade 3/4 neutropenia
8 (7) ± ± 11 (2) ± ±
Infection without grade 3/4
neutropenia
4 (4) ± ± 6 (1) ± ±
*For literal terms, 1, mild; 2, moderate; 3, severe; 4, life-threatening.
Table 4. Characteristics of delayed-onset diarrhoea in 580 evaluable cycles
Diarrhoea
Characteristic All grades Grade 3/4
Cycles with diarrhoea (%) 350 (60) G3: 38 (7)
G4: 3 (< 1)
Median time in days to ®rst onset (range) 6 (1±25) 6 (1±11)
Median duration in days (range) 3 (1±22) 5 (1±17)
Median no. of stools per day (range) 3 (1±21) 6 (2±21)
No. (%) of cycles resulting in:
Nocturnal stools 140 (24) 30 (5)
Abdominal pain 183 (32) 32 (6)
Blood 6 (1) 1 (< 1)
No. (%) cycles resulting in patient treatment 280 (48) 40 (7)
No. (%) cycles resulting in patient hospitalisation 21 (4) 16 (3)
No. (%) cycles resulting in patient rehydration 47 (8) 21 (4)
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their ®rst episode at cycle 1. Diarrhoea led to discontinuation
of treatment in two cases (2%). The incidence of fever and/or
infection was increased in the presence of grade 3 or 4 diar-
rhoea, as shown in Table 5. Furthermore, there was an even
higher incidence of fever and/or infection if there was con-
comitant grade 3 or 4 diarrhoea and grade 3 or 4 neu-
tropenia.
The cholinergic syndrome consists of abdominal cramps,
sweating, salivation, diarrhoea, malaise and hypotension. 88
patients (82%) and 275 cycles (47%) had at least one choli-
nergic symptom but severe events were uncommon. Atropine
sulphate was required in 104 cycles (18% of all cycles; 38%
of those with cholinergic syndrome). In no case was dis-
continuation of CPT-11 required, although the dose was
reduced in two cycles and the infusion interrupted in ®ve.
The syndrome appeared at the ®rst cycle in 77/88 (88%) of
aVected patients. In patients aVected by severe cholinergic
syndrome, atropine was used prophylactically in 113 sub-
sequent cycles, of which 46 (41%) were free of any choliner-
gic symptoms.
Nausea and vomiting occurred in 94 patients (88%) and
325 cycles (55%) and was severe (grade 3 or 4) in 20 patients
(19%) and 57 cycles (10%). Curative anti-emetic therapy was
required in 216/325 aVected cycles (66%). In no case was
cessation of CPT-11 treatment required.
Quality of life
Although not easily interpretable in a non-randomised
study, the median Global Health Status improved with suc-
cessive cycles, probably due to selection of patients with
treatment bene®t. When only patients still on study at cycle 6
were considered, the median Global Health Status remained
stable across the 6 cycles (baseline 66.7; subsequently ran-
ging from 66.7±83.3). When considering the global health
status of patients with at least 6 cycles, it was higher than that
of patients with 3 cycles at the most. Their status improved
whilst that of patients leaving the study early decreased. This
trend in time may be indicative of a treatment bene®t. The
median global health status of patients who had a PR was
75.9 compared with 63.1 in non-responders and 58.3 in
patients with progression as a best response.
DISCUSSION
This prospective study in patients with well-documented 5-
FU-resistant metastatic CRC shows that CPT-11 at a dose of
350 mg/m2 once every 3 weeks is an eVective treatment. The
overall response rate was 13.7% and the probability of being
free of progression at 4 months (6 cycles) was 50%. The
median survival from the start of second-line treatment was
10.4 months, which is of clinical importance in patients with
metastatic CRC that has failed 5-FU therapy, especially as
they had poor prognostic factors: strictly de®ned progression
on 5-FU within a short period of time (median 3.2 months);
short interval (median 1.5 months) from progression to start
of treatment with CPT-11 (both excluding slow-growing
tumours); 45% of patients had pain at entry to the study,
whereas most ®rst-line patients with CRC are asymptomatic.
The response rate of 13.7% in the present study is con-
sistent with that reported in the subgroup of patients with 5-
FU resistant disease in the earlier French multicentre study
and American studies [11, 12]. The response rate to second-
line CPT-11 in the present study compares favourably with
5-FU in ®rst-line therapy (18%). Responses were seen on
CPT-11, whatever the response to prior 5-FU was. A
response rate of 21% (7/33) was observed among the patient
subgroup which had disease progression as the best response
to prior 5-FU therapy and of 18% (3/17) among the patient
subgroup having PR/CR as best response. These data con-
®rm the lack of clinical cross-resistance between 5-FU and
CPT-11.
The majority of second-line regimens are currently 5-FU-
based, using diVerent schedules of administration and/or
modulator agents. Published results concern small studies
with a heterogeneous selection of regimens and methods of
assessment, the great majority having no independent review
of responses. Certainly none is directly comparable with the
present study and neither can any of the various 5-FU-based
regimens described in the literature be regarded as having
been validated or representing a standard. The response rates
in full publications range from 0±25% [7, 14±20]. It is note-
worthy that most of the objective responses observed with 5-
FU-based second-line regimens occurred either in patients
who had previously responded to 5-FU or in patients who
had previously received suboptimal doses of 5-FU. Indeed it
appears that previous treatment with 5-FU/LV regimens
predicts a poor response to a second 5-FU-based regimen
[7].
Other new chemotherapeutic agents have also been tried
after 5-FU failure in CRC, but mostly in very small studies
and usually with little success. Response rates are rarely (and
then not reproducibly) above 10% with any of the new agents
tested [20]. Oxaliplatin has also a relatively low activity as
single agent in second line treatment [21, 22], but one small
phase II trial reported an unusual high response rate in sec-
ond line treatment with the combination of oxaliplatinÐ5-
FU/LV [23].
In addition to the encouraging response rate in the present
study, there was a high rate of disease stabilisation (44.2%)
which was of long duration (median 4.8 months) and a
median time to disease progression of 3.9 months or 17
weeks. This median time to progression is clinically mean-
ingful in terms of tumour-growth control in patients with
documented rapid prior progression at study entry, since it is
accompanied by improvement or stabilisation of weight and
PS in a majority of patients. It would indeed have been
expected that all such patients with rapid progression on 5-
FU would have progressed on an ineVective treatment, with
deterioration in PS, weight loss and onset or worsening of
tumour-related symptoms. The global health status, as eval-
uated by the EORTC-QLQ-C30 questionnaire, was in this
study higher in patients who received 6 cycles compared with
patients who received 3 cycles at the most.
Other studies have shown that stabilisation of progressive
CRC is associated with both prolonged survival and sub-
jective improvement. An analysis of the relationship between
tumour response and survival in chemotherapy of advanced
Table 5. Number and percentage of cycles resulting in fever and/or
infection according to neutropenia and diarrhoea
WHO grade of neutropenia
WHO grade of diarrhoea
0, 1 or 2 3 or 4
0, 1 or 2 12/437 (3%) 11/86 (13%)
3 or 4 2/34 (6%) 2/7 (29%)
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colorectal cancer [24] has shown that any degree of objective
tumour response of 4 months duration is associated with a
de®nite survival advantage. The survival advantage conferred
by SD was almost as great as that associated with PR. In a
prospective study of quality of life using interviews or ques-
tionnaires during chemotherapy for advanced CRC [25]
bene®t in terms of quality of life was associated with anti-
tumour eVect, which did not necessarily have to be suY-
ciently large to qualify as an objective response on WHO
criteria.
The present study also provides important safety data
which indicate that the safety pro®le of CPT-11 is becoming
better understood and more amenable to medical manage-
ment. There were no deaths attributed to CPT-11 in the
present study. Eighty-two per cent of cycles were given at the
initial planned dose level and the median relative dose inten-
sity was 0.97.
Twenty-®ve per cent of patients in the present study
required hospitalisation for drug-related adverse events,
compared with 21% patients who received the Mayo Clinic
regimen of 5-FU/LV in a recent study [26]. In the present
study diarrhoea was a causal event in 15/27 (56%) of patients
requiring hospitalisation for adverse events.
The most frequent and severe non-haematological toxicity
was delayed-onset diarrhoea. Compared with previous pub-
lished experience in a comparable setting [12] the overall
incidence of this toxicity was similar, but the incidence of
grade 3 or 4 delayed diarrhoea in the present study was less
(26% of patients compared with 39% in the previous study
and 7% of cycles compared with 12%) as was the rate of
cessation of treatment due to this toxicity (2% compared with
10%) and the median duration of diarrhoea was shorter (3
days; range 1±22, as compared with 5 days; range: 1±34).
In conclusion, approximately 50% of patients with meta-
static CRC that has progressed on a single previous 5-FU-
based palliative chemotherapy are likely to bene®t in terms of
tumour growth control from treatment with CPT-11 350 mg/
m2 administered once every 3 weeks. This tumour growth
control is re¯ected in clinical bene®t, in terms of improve-
ment or stabilisation of weight and PS, and pain relief. In
addition, the safety pro®le of CPT-11 is becoming better
understood and more amenable to medical management.
CPT-11 represents a signi®cant step forward in this tradi-
tionally chemoresistant disease and its assessment in ®rst-line
chemotherapy is, therefore, warranted.
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